BacterioScan, Inc. is a medical device company dedicated to changing the way infectious disease is diagnosed and treated. We are driven by a fundamental desire to ensure the successful use of antibiotics. Our innovative instrumentation platform is built on the fast detection and antibiotic susceptibility testing of infectious pathogens. We produce reliable, precision instrumentation that quickly detects and measures microorganism growth in liquid specimens, determines if it is resistant to a range of antibiotics and provides clinicians with patient-specific guidance on the fastest and most cost-effective antibiotic treatment. Our technologies help to improve the quality of antibiotic therapy, reduce excess or inappropriate use of antibiotics and deter antibiotic resistance. The real-time bacteria detection and antimicrobial resistance data we collect and aggregate through our network can be used to inform clinical decision-making and the medical community’s response to emerging threats related to infectious disease and antibiotic resistance worldwide.
Looking for a particular BacterioScan Inc. employee's phone or email?
The BacterioScan Inc. annual revenue was $5.3 million in 2026.
Mike Thaman is the Chairman and CEO of BacterioScan Inc..
8 people are employed at BacterioScan Inc..
BacterioScan Inc. is based in St. Louis, Missouri.
The NAICS codes for BacterioScan Inc. are [334, 33].
The SIC codes for BacterioScan Inc. are [384, 38].